

## BioGaia's Board makes decision regarding extra dividend

**In light of the continued uncertainty in connection to the global spread of Covid-19, BioGaia's Board of Directors has decided not to convene an Extraordinary General Meeting to decide on the previously proposed extra dividend of SEK 4.25 per share.**

For precautionary reasons, and to ensure that BioGaia can act from a strong position in the current turbulent global situation, the Board believes that it is justified to withdraw the proposal for an extra dividend.

The Board's previous proposal, which was published in the Year-end report 2019, 6 February 2020, entailed an ordinary dividend of SEK 3.75 per share and an extra dividend of SEK 4.25 per share, a total of SEK 8.00 per share. 3 April 2020 the company announced that the Board, due to the current covid-19 situation, had decided to withdraw the proposal for an extra dividend and that a decision on this would be made later in the year, when a better overview of the effects of the ongoing pandemic could be obtained.

### **For additional information please contact**

Isabelle Ducellier, President and CEO, telephone: +46 8 555 293 00

### **Latest press releases from BioGaia**

13.08.2020	BioGaia Interim report 1 January – 30 June 2020
08.05.2020	Annual General Meeting of BioGaia
07.05.2020	BioGaia Interim report 1 January – 31 March 2020

This information is information that BioGaia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the CEO, 10 September 2020 at 10:30pm CET.

*BioGaia is an innovative Swedish healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are sold through local distribution partners in more than 100 countries worldwide. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. [biogaia.com](http://biogaia.com)*